Sigilon Therapeutics Names Cox to Board of Directors
10 May 2019 - - US-based biopharmaceutical company Sigilon Therapeutics has appointed biopharma executive John Cox, MBA, to its board of directors, the company said.

Cox has over 25 years of experience in biopharmaceuticals, most notably in his former role as chief executive officer of Bioverativ.

In that role, Cox built, grew and led the company to an USD 11.6bn acquisition by Sanofi, which was considered one of the most successful spinouts in biopharma history.

Cox is currently executive chairman of Torque Therapeutics.

Preceding his work at Bioverativ, Cox served in several key roles at Biogen, where he oversaw the company's production facilities, supply chain operations, technical development, quality and engineering across the globe.

Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics.

To create Shielded Living Therapeutics, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body.

These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D. and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.